He was the chairman of the Safety Monitoring Committee of the clinical trial. According to the complaint, when Martoma received the actual and detailed results of the clinical trial from Gilman, the hedge fund portfolios and investment advisers managed by CR Intrinsic liquidated their combined long-positions in Elan and Wyeth worth more than $700 million. They also made substantial short positions in Elan Corporation, plc (NYSE:ELN) and Wyeth Limited (NSE:WYETH) worth approximately $960 million in securities and eventually sold it in just one week. According to the prosecutors in the case, Martoma received a $9.4 million bonus in January 2009, based on the profits made by hedge funds from their trades in Wyeth and Elan Corp.